Delivery of toll-like receptor 3 ligand poly(I:C) to the liver by calcium phosphate nanoparticles conjugated with an F4/80 antibody exerts an anti-hepatitis B virus effect in a mouse model. (1st October 2021)

• Record Type: Journal Article
• Authors: Du, Yanqin; Yang, Xiaoli; Li, Jia; Sokolova, Viktoriya; Zou, Shi; Han, Meihong; Yan, Hu; Wey, Karolin; Lu, Mengji; Dittmer, Ulf; Yang, Dongliang; Epple, Matthias; Wu, Jun
• Is Part Of: Acta biomaterialia. Volume 133(2021)
• Page Start: 297
• Page End: 307
• Publication Date: 2021-10-01
• Subjects: Nanoparticles -- TLR3 ligands -- F4/80 -- Hepatitis B virus; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2021.01.045
• Languages: English
• ISSNs: 1742-7061

Abstract

Abstract: Hepatitis B virus (HBV) is a global health issue, but currently available anti-HBV drugs have limited success. Previously, introduction of the Toll-like receptor (TLR)-3 ligand poly(I:C) to the liver via hydrodynamic injection (HI) was shown to effectively suppress HBV replication in a chronic HBV replication mouse model. However, this method cannot be applied in human beings. To improve the liver targeting of poly(I:C) via intravenous injection, calcium phosphate nanoparticles (CPNs) carrying poly(I:C) with or without antibodies were constructed, and their anti-HBV effects were investigated. We found that significantly more anti-F4/80-conjugated and IgG2α-conjugated nanoparticles were taken up in liver cells both in vivo and in vitro . In addition, these nanoparticles produced pronounced immunostimulatory effects in vitro in primary liver cells. Importantly, treatment with nanoparticles carrying poly(I:C) increased the production of intrahepatic cytokines and chemokines and enhanced T cell responses, significantly reducing HBsAg, HBeAg and HBV DNA levels in the mice. Compared to nonconjugated and isotype-antibody-conjugated nanoparticles, the anti-F4/80-conjugated nanoparticles demonstrated the strongest anti-HBV effects. In summary, nanoparticles carrying poly(I:C) conjugated with an F4/80 antibody promoted liver targeting, and they may represent a suitable alternative to HI for future anti-HBV treatment. Statement of significance: HBV chronically infects approximately 250 million individuals worldwide but current anti-HBV drugs have limited success. Introduction of toll-like receptor 3 ligand poly(I:C) into liver by hydrodynamic injection has been proven to promote HBV clearance in mouse model. However, this technique is not clinically suitable for human patients. We have constructed calcium phosphate nanoparticles carrying poly(I:C) with specific antibody targeting liver nonparenchymal cells. The uptake into relevant liver cells and the anti-HBV effects were studied. After intravenous injection into mice, the uptake rate of anti-F4/80-conjugated nanoparticels was enhanced in liver, and these nanoparticles exert effective anti-HBV effects in vivo . This may provide important insight into future HBV immunotherapy based on nanoparticle-mediated drug delivery. Graphical abstract: Image, graphical abstract